A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Phesgo® Biosimilar HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Qi Jin
- Número de telefone: 86 159 5516 0489
- E-mail: Qi_jin@henlius.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Voluntary participation in the clinical study and signed the Informed Consent Form (ICF).
- Male or female aged ≥ 18 years old at the time of signing the ICF;
- Histologically confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 (HER2) positive confirmed by central laboratory.
- Participants agree to undergo surgery while meeting the criteria for surgery after neoadjuvant therapy.
- Left ventricular ejection fraction (LVEF) at baseline ≥ 55%.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- Adequate major organ functions.
- Women with child-bearing potential have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective contraceptive measures until 7 months after last dose.
Exclusion Criteria:
- Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
- History of other malignancy within 5 years.
- Prior systemic therapy for breast cancer treatment or radiotherapy.
- Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
- Patients who have undergone excision biopsy of the primary tumor and/or axillary lymph nodes or lymph node dissection.
- Have severe heart disease or medical conditions.
- Participants with viral hepatitis or those with autoimmune hepatitis, sclerosing cholangitis, or liver cirrhosis.
- Human Immunodeficiency Virus (HIV) infection, HIV antibody positive.
- Daily use of corticosteroid treatment is required.
- Sensitivity to any study medications or any of its ingredients or excipients.
- Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
- Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
- Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
- Any other conditions which are inappropriate for the study in the opinion of the investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: HLX319
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
|
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
|
Comparador Ativo: EU-Phesgo®
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
|
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Peak concentration (Cmax)
Prazo: up to 180 days
|
Peak concentration after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Prazo: up to 180 days
|
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Steady-state peak concentration (Cmax,ss)
Prazo: up to 180 days
|
The steady-state peak concentration after multiple doses administration in Cycle 4.
|
up to 180 days
|
|
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Prazo: up to 180 days
|
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
|
up to 180 days
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Trough concentration (Ctrough)
Prazo: up to 180 days
|
Trough concentration after a single dose administration
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Prazo: up to 180 days
|
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
|
up to 180 days
|
|
Percentage of extrapolated area in the total AUC (%AUCex)
Prazo: up to 180 days
|
Percentage of extrapolated area in the total AUC after a single dose administration
|
up to 180 days
|
|
Time to peak concentration (Tmax)
Prazo: up to 180 days
|
time to peak concentration after a single dose administration
|
up to 180 days
|
|
Elimination half-life (T1/2)
Prazo: up to 180 days
|
elimination half-life after a single dose administration
|
up to 180 days
|
|
Total clearance (CL/F)
Prazo: up to 180 days
|
total clearance after a single dose administration
|
up to 180 days
|
|
Terminal phase distribution volume (Vz/F)
Prazo: up to 180 days
|
terminal phase distribution volume after a single dose administration
|
up to 180 days
|
|
Mean residence time (MRT)
Prazo: up to 180 days
|
mean residence time after a single dose administration
|
up to 180 days
|
|
Steady-state trough concentration (Ctrough,ss)
Prazo: up to 180 days
|
steady-state trough concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Average steady-state concentration (Caverage,ss)
Prazo: up to 180 days
|
average steady-state concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state time to peak concentration (Tmax,ss)
Prazo: up to 180 days
|
steady-state time to peak concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Elimination half-life (T1/2,ss)
Prazo: up to 180 days
|
elimination half-life after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state volume of distribution (Vss/F)
Prazo: up to 180 days
|
steady-state volume of distribution after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state total clearance (CLss/F)
Prazo: up to 180 days
|
steady-state total clearance after multiple doses administration in Cycle 4
|
up to 180 days
|
|
accumulation ratio based on Cmax (RCmax)
Prazo: up to 180 days
|
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Accumulation ratio based on AUC (RAUC)
Prazo: up to 180 days
|
accumulation ratio based on AUC after multiple doses administration in Cycle 4
|
up to 180 days
|
|
The total pathological complete response (tpCR) rate assessed by the investigator
Prazo: up to 180 days
|
up to 180 days
|
|
|
Breast pathologic complete response (bpCR) rate assessed by the investigator
Prazo: up to 180 days
|
up to 180 days
|
|
|
Objective response rate (ORR) assessed by the investigator
Prazo: up to 180 days
|
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
|
up to 180 days
|
|
Incidence and severity of adverse events (AEs)
Prazo: up to 180 days
|
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
|
up to 180 days
|
|
Number of participants with abnormal vital signs
Prazo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal physical examination findings
Prazo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal Laboratory tests results
Prazo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal 12-lead ECG readings
Prazo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Positivity rates of anti-drug antibodies (ADA)
Prazo: up to 180 days
|
up to 180 days
|
|
|
Positivity rates of neutralizing antibodies (NAb)
Prazo: up to 180 days
|
up to 180 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- HLX319-BC001
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .